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Abstract
Background: The epidermal growth factor receptor (EGFR) is over-expressed in 70–75% of
colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has been
approved for the treatment of metastatic CRC, however tumor response to cetuximab has not
been found to be associated with EGFR over-expression by immunohistochemistry (IHC). The aim
of this study was to explore EGFR and the downstream effector phosphatase and tensin homologue
deleted on chromosome 10 (PTEN) as potential predictors of response to cetuximab.
Methods: CRC patients treated with cetuximab by the Hellenic Cooperative Oncology group,
whose formalin-fixed paraffin-embedded tumor tissue was available, were included. Tissue was
tested for EGFR and PTEN by IHC and fluorescence in situ hybridization (FISH).
Results: Eighty-eight patients were identified and 72 were included based on the availability of
tissue blocks with adequate material for analysis on them. All patients, except one, received
cetuximab in combination with chemotherapy. Median follow-up was 53 months from diagnosis and
17 months from cetuximab initiation. At the time of the analysis 53% of the patients had died. Best
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response was complete response in one and partial response in 23 patients. In 16 patients disease
stabilized. Lack of PTEN gene amplification was associated with more responses to cetuximab and
longer time to progression (p = 0.042).
Conclusion: PTEN could be one of the molecular determinants of cetuximab response. Due to
the heterogeneity of the population and the retrospective nature of the study, our results are
hypothesis generating and should be approached with caution. Further prospective studies are
needed to validate this finding.
Background
Activation of the epidermal growth factor receptor (EGFR)
is related to cell proliferation, metastasis and angiogenesis
in many tumors [1]. In colorectal carcinoma (CRC)
patients, EGFR is over-expressed in 75% of the tumors and
its over-expression is associated with worse outcome [2].
EGFR was therefore an obvious candidate for targeted
therapy in this malignancy. Cetuximab is an IgG1 anti-
EGFR monoclonal antibody (moAb) that binds to the lig-
and-binding domain of the EGFR, leading to inhibition of
its proliferative activity. Its use in the clinic has resulted in
response rates (RR) of 23–25% in combination with
chemotherapy and 10% as a single agent [3]. The most
common side effect of cetuximab is an acneiform rash,
which, however, seems to be positively associated with
response and overall survival [4].
In order to avoid the unnecessary use of a costly treat-
ment, investigators have been seeking molecular determi-
nants of response to cetuximab, so that it could be used
only on those patients that are most likely to derive a ben-
efit. Several studies have evaluated the significance of
EGFR over-expression as a surrogate marker for cetuximab
response, but no such correlation has been found [5,6].
EGFR gene amplification has also been evaluated by fluo-
rescence in situ hybridization (FISH) [7-9]. While EGFR
gene amplification by FISH seemed to be associated with
cetuximab benefit in one small retrospective study [9], in
prospective studies and when EGFR was measured by
quantitative polymerase chain reaction (PCR), its RNA
levels were not associated with clinical benefit [3]. A
small, recently published study confirmed the correlation
of EGFR gene amplification with response to cetuximab
[10].
A plausible explanation for the lack of an apparent corre-
lation of EGFR over-expression with benefit from cetuxi-
mab is that the activation or inactivation of downstream
effectors may also be necessary. One study evaluated the
role of intratumoral mRNA levels of EGFR effectors, such
as vascular endothelial growth factor (VEGF), interleukin
8 (IL-8), cyclin D1, and cyclooxygenase-2 (Cox-2) in pre-
dicting response to cetuximab [11]. In that study, gene
expression levels of Cox-2, EGFR and IL-8 were associated
with high overall survival on cetuximab, while low VEGF
levels correlated with response to cetuximab.
The most compelling data so far are those that correlate
the presence of K-RAS mutations with resistance to cetux-
imab [12]. In fact this is also the case for non-small-cell
lung cancer resistance to the anti-EGFR TKIs [13]. Interest-
ing information is also emerging in regards to the signifi-
cance of VEGF and hypoxia inducible factor 1 alpha
(HIFa) in the mechanism of action of cetuximab [14].
Phosphatase and tensin homologue deleted on chromo-
some 10 (PTEN) loss has been shown to be associated
with resistance to trastuzumab [15], which is a mono-
clonal antibody against another EGF family receptor,
Her2Neu. As Her2Neu and EGFR form heterodimers and
use the same downstream signaling pathways, it was rea-
sonable to test PTEN as a potential determinant of cetuxi-
mab resistance. This has been explored already by one
group. In this recently published report immunohisto-
chemistry evaluated loss of expressing of PTEN was asso-
ciated with lack of response to cetuximab [10].
In the present retrospective study we collected data on all
patients treated with cetuximab by the Hellenic Coopera-
tive Oncology Group. Of note this study was performed
right after the approval of cetuximab. At the time the
investigators were using cetuximab off protocol in fairly
advanced patients and in various lines and combinations.
This, therefore, is a heterogeneous population which,
however, is quite representative of common practice in
Greece.
We then investigated in formalin-fixed paraffin-embed-
ded (FFPE) tissue the protein expression and gene status
of EGFR and PTEN. Association of these parameters with
treatment response, progression free and overall survival
from diagnosis and cetuximab initiation was explored.
Methods
All patients with histologically confirmed, locally
advanced or metastatic colorectal cancer, who had been
treated with cetuximab off protocol, alone or in combina-
tion with chemotherapy, by the Hellenic CooperativeBMC Cancer 2008, 8:234 http://www.biomedcentral.com/1471-2407/8/234
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Oncology Group (HeCOG) between January 2004 and
September 2005 were identified. The investigators were
asked to obtain FFPE tissue from each patient for molecu-
lar analysis. Patients whose tissue was available were
asked to consent for this analysis and then the tissue block
was obtained and clinical data were collected.
Eighty-eight patients were identified and archival FFPE
tumor samples were available for 75 patients. The mate-
rial consisted of invasive or metastatic colorectal adeno-
carcinoma tissue, obtained from surgical resection
specimens. All tissue blocks were re-cut and reviewed by
the pathology team for confirmation of the diagnosis and
adequacy of the material. After the evaluation 72 cases
were selected for the study.
This research was carried out in compliance with the Hel-
sinki Declaration and Ethics Committee approvals were
obtained where appropriate.
IHC
EGFR immunoreactivity was investigated using the EGFR
(31G7, Zymed) mouse moAb, as previously described
[16]. For EGFR staining interpretation, the proposed crite-
ria by DakoCytomation EGFR pharmDx kit were used in
correlation with the definitions by Italiano et al [17]. Sec-
tions were considered positive when ≥ 1% of the tumor
cells had membranous staining above the background
level and the intensity of EGFR reactivity was scored as +1,
+2 and +3. Tumors with moderate (+2) and strong (+3)
expression were considered as having EGFR protein over-
expression [18]. Any cytoplasmic staining was considered
non-specific and theses cases were evaluated as negative.
Furthermore we performed IHC assays for the detection of
PTEN (28H6, Novocastra, U.K.). Nuclear PTEN protein
expression was evaluated according to a previously estab-
lished rank scale of 0 to 2 [19]. Inflammatory and normal
stromal cells were used as control markers of staining
intensity. PTEN staining in tumor cells was graded as: 2, if
the staining intensity was equal to or higher than that of
control cells; 1, if their staining intensity was lower than
that of control cells; and 0, if no staining was found in the
tumor cells. Tumors with PTEN scores of 0 or 1 were con-
sidered to have PTEN loss. Cases with staining of 2 in
more than 10% of the cells were considered positive for
PTEN expression by IHC.
The evaluation of all IHC sections was done simultane-
ously by three pathologists, blinded as to the patients'
clinical characteristics and survival data. All the stained
slides were compared to appropriate positive and negative
control sections.
Fluorescence in situ hybridization (FISH)
Whole tissue sections (4 μm thick) were used for FISH
analysis. The commercially available probes for the EGFR
gene (LSI EGFR/CEP 7 Dual Color Probe, Vysis, U.S.A.)
and PTEN gene (LSI® PTEN/CEP 10 Dual Color Probe,
Vysis) were used. The procedures were performed accord-
ing to the manufacturer's instructions with slight modifi-
cations. Hybridization signals were enumerated using a
Zeiss fluorescence microscope (Axioskop 2 plus HBO
100) equipped with an oil immersion ×100 objective, an
appropriate filter set (DAPI, FITC/spectrum green, rhod-
amine/spectrum orange) and a computerized imaging
system (FISH Imager™ METASYSTEMS).
FISH analysis
The evaluation of the FISH sections was done simultane-
ously by two observers. The cut-off values for each probe
were determined using the mean percentage of probe sig-
nals obtained from scoring 100 cells per case, from 8 nor-
mal colon tissue samples and was set at the mean plus or
minus two standard deviations (SD). For the evaluation of
the EGFR and PTEN gene status, 100 non-overlapping
nuclei of tumor cells were also randomly selected and
scored from each tumor section. Images were captured
with a computer-controlled digital camera and processed
with a software system (FISH Imager). The following cri-
teria were used for the evaluation of FISH: For each FISH
probe tested, the status of the chromosome (defined by
the presence of centromeric probe-CEP signals) was used
as control. The status of the respective gene and the ratio
gene probe/centromeric probe was calculated. FISH pat-
terns were considered normal when the ratio of the gene
copies/chromosome number in each case was from 0.9–
1.2 for EGFR [20] and 0.85–1.15 for PTEN (mean ± 2SD).
Values below or above the respective cut-offs were consid-
ered as gene deletion or gene gain, respectively.
Statistical analysis
Data on selected patient or tumor characteristics, prior
treatments, response, skin toxicity, TTP following each
treatment with cetuximab and survival were extracted
from the records. TTP was estimated from initiation of
each different line of treatment with cetuximab to the date
progression of disease was documented. Survival was cal-
culated from the date of diagnosis as well as from the first
date of cetuximab treatment to the date of last contact or
to the date of death from any cause. All survival probabil-
ities were assessed according to the Kaplan-Meier method,
whereas the log rank test was used to assess the effect of
molecular markers on survival and TTP. Fisher's exact test
was used to compare the results from IHC and FISH for
the several molecular markers with respect to response
and skin toxicity. All tests were two sided and a p-value of
0.05 or less was considered statistically significant. No
multiple testing p-value adjustment was performed sinceBMC Cancer 2008, 8:234 http://www.biomedcentral.com/1471-2407/8/234
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this was only an exploratory analysis of retrospectively
collected data in a very heterogeneously treated popula-
tion.
Ethics approval
The protocol was approved by the HeCOG Protocol
Review Committee (HE R_6ER/05-22/10/2005) and by
the Bioethics Committee of Aristotle University of Thessa-
loniki School of Medicine (A945-25/10/2005).
Results
Seventy-two cetuximab treated patients (40 male and 32
female) were analyzed. Median age was 60 years. Most
patients (52 of 72) had left sided (rectosigmoid) tumors
and all except one had undergone surgery at the time of
diagnosis. Duke's stage at diagnosis was: D for 39 (54%)
of the patients; C for 19 (26%) and B for 12 (17%). Fifty-
three patients (74%) had grade II disease. At the time of
cetuximab therapy 54 patients (75%) had liver metastases
and 31 (43%) had lung metastases. Other sites of metas-
tases were lymph nodes, the abdomen and pelvis, bones,
adrenals, brain, and spleen (Table 1). Ascites was recorded
in 3 patients.
Median follow-up was 53 months from diagnosis and 17
months from cetuximab initiation. At the time of the anal-
ysis 38 patients (53%) had died, most of them of disease.
Two patients died of cardiovascular causes. Median over-
all survival from first colorectal cancer diagnosis was 46.8
months and from cetuximab initiation 14.9 months.
Cetuximab was given in combination with various regi-
mens in all patients except one, who was treated with sin-
gle agent cetuximab only. Two additional patients were
treated with cetuximab alone after receiving it in combi-
nation with other regimens.
The most commonly used chemotherapeutic regimens
were FOLFIRI in 27 patients, FOLFOX in 18 patients and
irinotecan in 13 patients. A high percent of the patients
(68%) were treated in second or third line, while 8.5%
were treated in 1st line, 15% in 4th, and 8.5% in 5th line.
Median time to progression (TTP) for patients treated in
first to fourth line was between 6.2 and 7.6 months.
Patients treated with cetuximab twice had a median TTP
of 6.6 months the first time and 2.7 months the second
time.
One patient achieved a complete response twice, both
times in combination with irinotecan. Notably, this
patient had lymph node only disease and very high EGFR
amplification by FISH and normal PTEN. He progressed
both times soon after stopping cetuximab maintenance
and eventually died of disease.
Table 1: Selected patient and tumor characteristics
N7 2
Age
Median 60.1
Range 29–76
N%
Sex
Male 40 56
Female 32 44
Concurrent illness
No 44 61
Yes 28 39
Initial Surgery
No 1 1
Yes 71 99
Radical Operation
No 24 33
Yes 48 67
Family history of neoplasia
No 47 65
Yes 22 31
Unknown 3 4
Previous history of cancer
No 69 96
Yes 3 4
Previous adjuvant treatment
No 46 64
Yes 24 33
Unknown 2 3
Primary site
Cecum 6 8
Ascending 7 10
Transverse 5 7
Descending 2 3
Sigmoid 32 44
Rectum 20 28
Stage
B1 1 1
B2 11 15
C1 3 4
C2 16 22
D3 9 5 4
Unknown 2 3
Histology grade
I5 7
II 53 74
III 9 12
Unknown 5 7
Metastatic sites of disease
Liver 54 75
Abdomen 8 11
Pelvis 3 4
Lung 31 43
Nodes 9 12
Bones 7 10
Adrenals 2 3
Serologic relapse 4 6
Other 4 6
Values were rounded upBMC Cancer 2008, 8:234 http://www.biomedcentral.com/1471-2407/8/234
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62 patients were treated with cetuximab only in one line
of therapy, while 10 were treated in two lines, for a total
of 82 lines of treatment with cetuximab. Best response was
CR in one patient, partial response (PR) in 23 and stable
disease (SD) in 16 (two patients experienced CR and PR
each, twice) (Table 2, Table 3). Skin toxicity (all grades)
was encountered in 57 of 82 lines of treatment with cetux-
imab. Some degree of rash was seen in 21 of 24 lines of
treatment leading to PR and in both lines of treatment in
the patient who achieved CR, though grade 2 and 4 rash
was only seen in 39 of 82 lines of treatment. Response to
cetuximab was seen in 12.5% of patients with no rash ver-
sus 40% of patients who developed some degree of rash
(p = 0.019).
Biomarker expression and gene status analysis
A summary of the IHC and FISH findings are presented in
Table 4. Membranous staining of EGFR protein expres-
sion was detected in 38/71 cases (54%), while over-
expression (+2, +3) in 13 of the 38 EGFR-positive cases
(34%). PTEN protein expression (no loss) was observed
in 62/72 cases (86%) and the percentage of stained tumor
cells in these cases ranged from 20% to over 90% (Figure
1). The majority of the patients showed PTEN nuclear
staining, whereas nuclear and cytoplasmic staining was
observed in 2 cases.
EGFR gene status assessed by FISH, according to the crite-
ria described above, was normal in 56/66 cases (85%).
EGFR gene gain was observed in 5 cases, whereas gene
deletion was seen in 5 cases, 4 of which were accompa-
nied by lack of protein expression. PTEN gene deletion
was observed in 23/66 cases (35%) (Figure 2).
No influence of EGFR expression as assessed by IHC and
FISH or PTEN expression as assessed by IHC TTP and
response to cetuximab was found.
More responses to cetuximab were seen in patients with
wild type PTEN by FISH (see Tables 4 and 5). PTEN dele-
tion was also associated with a significantly shorter TTP in
the first line of treatment with cetuximab (deletion 5.28
months vs. normal 7.41 months, p = 0.042) (Figure 3).
Discussion
Although a number of EGFR targeted agents are approved
for clinical use, in most cases the molecular determinants
of response and resistance are not clear. EGFR is a trans-
mebrane tyrosine receptor with kinase activity, which is
over-expressed in many tumors. EGFR over-expression
however, does not seem to be associated with response to
and survival on cetuximab. In the present study we found
that wild type PTEN was associated with response to and
TTP on cetuximab. PTEN has been found to confer resist-
ance to EGFR-inhibitors in glioblastoma, prostate, breast
and non-small-cell lung cancer [15], and this resistance
appears to be due to its function as a negative regulator of
the phosphatidylinositol 3' kinase (PI3K) complex. PTEN
inactivation leads to uncontrolled signaling trough the
protein kinase B (PKB)/Akt pathway and to PIP3 accumu-
lation, which in turn dissociates EGFR inhibition from the
inhibition of the downstream signaling through this path-
way. Whether inactivation of this pathway is sufficient for
EGFR resistance is not clear. In a pre-clinical study it was
shown that the induction of excess Akt in a PTEN normal,
EGFR amplified cell line, alone, did not reverse sensitivity
to an EGFR kinase inhibitor [21]. On the other hand,
more recent in vitro studies support the significance of Akt
accumulation in this setting [22].
In this study we investigated a segment of the colorectal
cancer pathway, involved in the signaling of the EGFR
pathway, in an effort to discover molecular determinants
Table 2: Response by line of treatment
Response
Chemotherapy Line CR PR SD PD NE
1st 12 2 1 1
2nd 19 9 1 0 3
3rd -8 5 8 3
4th -4 1 5 2
5th -1 - 6 -
Total 22 4 1 7 3 0 9
Table 3: Response by treatment combination
Response
Treatment combination CR PR SD PD NE
Cetuximab monotherapy - 1 - 1 -
Cetuximab+FU+Leucovorin+CPT-11 - 11 7 7 2
Cetuximab+FU+Leucovorin+Eloxatin - 7 2 8 1
Cetuximab+CPT-11+Eloxatin - - 1 1 2
Cetuximab+CPT-11+Capecitabine - - 1 2 1
Cetuximab+Eloxatin+Capecitabine - 2 2 - -
Cetuximab+CPT-11 2 2 2 7 -
Cetuximab+Eloxatin - - - - 1
---1-
--1--
Cetuximab+FU+CPT-11 - 1 - - -
Cetuximab+FU+Leucovorin - - 1 1 -
Cetuximab+CPT-11+Avastin - - - 1 -
Cetuximab+Capecitabine - - - 1 2
Total 22 4 1 7 3 09
Abbreviations: CR, complete response; PR, partial response; SD, 
stable disease; PD, progressive disease; NE, Non-evaluable.BMC Cancer 2008, 8:234 http://www.biomedcentral.com/1471-2407/8/234
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of cetuximab response. Due to the retrospective nature of
the study the results are not definitive and should be
approached with caution. In fact our group is analyzing
tissue from additional patients for several molecular
parameters and with more sophisticated techniques to
confirm these results. Indeed many of the techniques used
here are new and not standardized yet. Above all, these
data need to be tested in a prospective study.
Clearly our patient population is heterogeneous in terms
of combinations of previous chemotherapy received and
line of chemotherapy associated with cetuximab. How-
ever this heterogeneity is consistent with current off-pro-
tocol practice in Greece. Furthermore, patients received
cetuximab after failing the previous regimens and there-
fore could be considered resistant to them. This in turn
indicates probable association of treatment effect with
cetuximab use.
All these difficulties notwithstanding, it seems that we
have identified a parameter that may be associated with
cetuximab clinical benefit. The proposed mechanism,
implicating PTEN mutations in EGFR resistance, is biolog-
ically plausible and has been described by other investiga-
tors in other malignancies [15]. More importantly, the
recently published report by Frattini et al [10] also exam-
ined PTEN by IHC and discovered a correlation between
loss of PTEN protein expression and lack of response to
cetuximab. Even more recently another study examined
the effect of cetuximab on several colon cancer cell lines
and found that PTEN null, PIK3CA mutant and Ras/BRAF
mutants cell lines are resistant to cetuximab. The authors
even go as far as to recommend use of these parameters to
stratify patients likely to benefit from cetuximab [23].
However, since wild type PTEN is quite common (60–
100%) in colorectal adenocarcinoma, if it were the sole
determinant of cetuximab response one would expect
much higher response rates on cetuximab. Therefore it is
more likely that PTEN is only one of the parameters that
determine response to this therapeutic monoclonal anti-
body.
Whether PTEN is indeed a significant determinant of
EGFR inhibitor efficacy must be investigated further and
confirmed. Moreover, an optimal testing algorithm for the
determination of PTEN status must be defined and stand-
ardized, so that it can be used in identifying patients who
may be candidates for anti EGFR therapy. Finally, we will
have to assess the significance of the co-overexpression of
other molecules, such as MSI, VEGFR and K-RAS, as well
as other downstream molecules of the EGFR pathway.
Lastly, PTEN may also be inactivated via methylation and
this should also be explored further [24].
Table 4: Best response to treatment, and TTP on first line with cetuximab according to EGFR and PTEN status assessed by IHC and 
FISH
Number of patients Response Rate TTP on first line with cetuximab
(N = 72) N (%) (months)
IHC
EGFR
Negative 33 14 (42%) 6.85
Positive 38 10 (26%) 5.93
NE 1
P-value 0.60
PTEN
No loss 62 19 (31%) 6.39
Loss 10 5 (50%) 9.44
P-value 0.54
FISH
EGFR
Normal 56 20 (36%) 6.85
Gain 5 1 (20%) 8.72
Deletion 5 1 (20%) 6.39
NE 6
P-value 0.18
PTEN
Normal 43 18 (42%) 7.41
Gain - - -
Deletion 23 3 (13%) 5.28
NE 6
P-value 0.042
Abbreviations: NE, Non-evaluable, NRY, Not reached yetBMC Cancer 2008, 8:234 http://www.biomedcentral.com/1471-2407/8/234
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Conclusion
In conclusion, our clinical findings support previous data
showing that the moAb cetuximab is an effective thera-
peutic agent against colorectal cancer. The molecular
mechanisms of this response are complex, and probably
dependent upon the expression levels of several signaling
proteins of the EGFR and other pathways. PTEN, as sug-
gested by our findings, seems to be particularly significant
in this process.
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Kaplan-Meier curves for TTP according to PTEN expression (FISH) Figure 3
Kaplan-Meier curves for TTP according to PTEN expression (FISH).
Months 
26  24  22  20  18  16  14  12  10  8  6  4  2  0 
P
r
o
b
a
b
i
l
i
t
y
 
   1 
0,5 
  0 
Normal 
Deletion 
Log-Rank: p=0.042
the manuscript writing and final approval, PK conceived
of the study and participated in its design and in the
recruitment of patients, GF conceived of the study and
participated in its design, in the recruitment of patients, in
the collection and assembly of data and in the manuscript
writing and final approval.
All authors read and approved the final manuscript.
Acknowledgements
The authors wish to thank Ms. Sonia Chalkidou and Ms. Irene Grimani 
(MSc) HeCOG Data Office, Athens, for statistical analysis, Ms. Dimitra Kat-
sala HeCOG Data Office, Athens for monitoring the study, Mrs. Maria 
Moschoni, HeCOG Data Office, Athens, for data coordination and Ms. 
Thalia Spinari HeCOG Data Office, Athens for secretarial assistance. This 
study was supported in part by a HeCOG research grant (HE R_6ER/05).
References
1. Carpenter G, Cohen S: Epidermal growth factor.  J Biol Clin 1990,
265:7709-7712.
2. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H:
The prognostic significance of proliferating cell nuclear anti-
gen, epidermal growth factor receptor and mdr gene
expression in colorectal cancer.  Cancer 1993, 71:2454-2460.
3. Lenz HJ, Van-Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P,
Mirtsching B, Cohn AL, Pipas AW, Azarnia N, Tsuchihashi Z, Mauro
DJ, Rowinsky EK: Multicenter phase II and translational study
of cetuximab in Metastatic Colorectal Carcinoma refractory
to irinotecan, oxaliplatin and fluoropyrimidines.  J Clin Oncol
2006, 24:4914-4921.
4. Saltz LB, Kies M, Abbruzzesse JL, Azarnia N, Needle M: The pres-
ence and intensity of the cetuximab- induced acne-like rash
predicts increased survival in studies across multiple malig-
nances.  Proc Am Soc Clin Oncol 2003, 22:204. (A817)
5. Saltz LB, Meropol NT, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ:
Phase II trial of cetuximab in patients with refractory color-
ectal cancer that express the epidermal growth factor
receptor.  J Clin Oncol 2004, 22:1201-1208.
6. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton
A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP,
Saltz LB: Cetuximab shows activity in colorectal cancer
patients with tumors that do not express the epidermalPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:234 http://www.biomedcentral.com/1471-2407/8/234
Page 10 of 10
(page number not for citation purposes)
growth factor receptor by immunohistochemistry.  J Clin
Oncol 2005, 23:1803-1810.
7. Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J, Akram M,
Chung KY, Yao D, Paty PB, Gerald W, Chen B: Epidermal growth
factor receptor expression on gene amplification in colorec-
tal carcinoma. An immunohistochemical and chronogenic in
situ hybridization study.  Mod Pathol 2005, 18:1350-6.
8. Sauer T, Guren ML, Noren T, Dueland S: Demonstration of EGFR
gene copy loss in colorectal carcinoma by fluorescent in situ
hybridization (FISH) a surrogate marker for sensitivity to
specific anti-EGFR therapy?  Histopathology 2005, 47:560-4.
9. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A,
Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy
number of epidermal growth factor receptor (EGFR) and
clinical response to anti EGFR treatment in colorectal can-
cer: a cohort study.  Lancet Oncol 2005, 6:279-286.
10. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M,
Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L: PTEN loss of
expression predicts cetuximab efficacy in metastatic color-
ectal cancer patients.  British Journal of Cancer 2007, 97:1139-1145.
11. Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA,
Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ:
Molecular determinants of cetuximab efficacy.  J Clin Oncol
2005, 23:3536-3544.
12. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF,
Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Lau-
rent-Puig P: Kras mutation status is predictive of response to
cetuximab therapy in colorectal cancer.  Cancer Res 2005,
66:3992-3995.
13. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu
DD, Bekele BN, Herbst RS, Wistuba II: KRAS mutation is an
important predictor of resistance to therapy with epidermal
growth factor receptor tyrosine kinase inhibitors in non-
small- cell lung cancer.  Clin Cancer Res 13(10):2890-6. 2007 May
15
14. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z: The antiepidermal
growth factor receptor monoclonal antibody cetuximab/C
225 reduces hypoxia-inducible factor 1 alpha, leading to tran-
scriptional inhibition of vascular endothelial growth factor
expression.  Oncogene 2005, 24:4433-4441.
15. Mellinghoff IK, Cloughesy TF, Mischel PS: PTEN mediated resist-
ance to Epidermal Growth Factor Receptor Kinase inhibi-
tors.  Clin Cancer Res 2007, 13(2):370-382.
16. Fountzilas G, Karkavelas G, Kalogera-Fountzila A, Karina M, Ignatiadis
M, Koukoulis G, Plataniotis G, Bobos M, Pectasides D, Razis E, Kara-
velis A, Selviaridis P: Post-operative combined radiation and
chemotherapy with temozolomide and irinotecan in
patients with high-grade astrocytic tumors. A phase II study
with biomarker evaluation.  Anticancer Res 2006, 26:4675-4686.
17. Italiano A, Saint-Paul MC, Caroli-Bosc FX, Francois E, Bourgeon A,
Benchimol D, Gugenheim J, Michiels JF: Epidermal growth factor
receptor (EGFR) status in primary colorectal tumors corre-
lates with EGFR expression in related metastatic sites: bio-
logical and clinical implications.  Ann Oncol 2005, 16:1503-1507.
18. Bredel M, Pollack IF, Hamilton RL, James CD: Epidermal growth
factor receptor expression and gene amplification in high-
grade non-brainstem gliomas of childhood.  Clin Cancer Res
1999, 5:1786-1792.
19. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Kom-
minoth P, Lees JA, Mulligan LM, Mutter GL, Eng C: Immunohisto-
chemical evidence of loss of PTEN expression in primary
ductal adenocarcinomas of the breast.  Am J Pathol 1999,
155:1253-1260.
20. Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng
C, Baron AE, Franklin W, Said S, Varella-Garcia M: Epidermal
growth factor receptor and cyclin D1 are independently
amplified and overexpressed in esophageal squamous cell
carcinoma.  J Cancer Res Clin Oncol 2005, 131:111-119.
21. Mellinghoff IK, Wang MI, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ,
Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau
LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers
WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS:
Molecular determinants of the response of glioblastomas to
EGFR Kinase Inhibitors.  N Eng J Med 2005, 353:2012-24.
22. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N: The BAD
protein integrates survival signaling by EGFR/MAPK and
PI3K/Akt Kinase pathway in PTEN-deficient tumor cells.
Cancer Cell 2005, 8:287-297.
23. Minaxi Jhawer, Goel Sanjay, Wilson Andrew J, Montagna Cristina, Ling
Yi-He, Byun Do-Sun, Nasser Shannon, Arango Diego, Shin Joongho,
Klampfer Lidija, Augenlicht Leonard H, Soler Roman Perez, Mariada-
son John M: PIK3CA Mutation/PTEN Expression Status Pre-
dicts Response of Colon Cancer Cells to the Epidermal
Growth Factor Receptor Inhibitor Cetuximab.  Cancer Res
2008, 68(6):1953-61.
24. Khan S, Kumanagai T, Vora J, Bose N, Sehgal I, Koeffler PH, Bose S:
PTEN promoter is methylated in a proportion of invasive
breast cancers.  Int J Cancer 2004, 112(3):407-10.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/234/pre
pub